Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain EGRX message board posts where the ticker symbol EGRX has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest EGRX SEC Filings

Filings Format Description Filing Date File/Film Number
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000215457-18-006114 (34 Act)  Size: 13 KB
2018-10-10 005-88022
181116224
8-K  Documents Current report, items 7.01 and 9.01
Acc-no: 0001104659-18-060181 (34 Act)  Size: 2 MB
2018-10-03 001-36306
181103685
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001104659-18-060180 (34 Act)  Size: 44 KB
2018-10-03 001-36306
181103684
8-K  Documents Current report, item 5.02
Acc-no: 0001104659-18-058763 (34 Act)  Size: 24 KB
2018-09-26 001-36306
181088360
8-K  Documents Current report, items 7.01 and 9.01
Acc-no: 0001104659-18-056560 (34 Act)  Size: 2 MB
2018-09-13 001-36306
181068041
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001104659-18-054242 (34 Act)  Size: 72 KB
2018-08-30 001-36306
181045504
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0000827871-18-000008 (34 Act)  Size: 5 MB
2018-08-07 001-36306
18999198
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001104659-18-049991 (34 Act)  Size: 439 KB
2018-08-07 001-36306
18996260
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001104659-18-044211 (34 Act)  Size: 42 KB
2018-07-09 001-36306
18943377
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-041189 Size: 7 KB
2018-07-03
More EGRX SEC Filings


Related news from
Mon, 08 Oct 2018
12:06:38 +0000
See what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc NASDAQ NMS:EGRX
Wed, 03 Oct 2018
11:00:00 +0000
Eagle Pharmaceuticals Enters into Agreement with USAMRICD to Evaluate Neuroprotective Effects of RYANODEX Secondary to Nerve Agent Exposure
Eagle Pharmaceuticals, Inc. (EGRX) (“Eagle” or the “Company”) today announced that it has entered into an agreement with the United States Army Medical Research Institute of Chemical Defense (USAMRICD), the nation's leading science and technology laboratory in the area of medical chemical countermeasures research and development, to conduct a study to evaluate the neuroprotective effects of RYANODEX® (dantrolene sodium). The study will be conducted under a Cooperative Research and Development Agreement (CRADA), a written agreement that allows government laboratories to partner with private industries or academia on research and development projects.
Thu, 27 Sep 2018
11:00:00 +0000
Eagle Pharmaceuticals, Inc. To Present At Cantor Global Healthcare Conference
Eagle Pharmaceuticals, Inc. announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will pr
Wed, 26 Sep 2018
20:30:00 +0000
Eagle Appoints David Pernock to Position of Chief Operating Officer
Eagle Pharmaceuticals, Inc. today announced that the Compensation Committee of the Company’s Board of Directors has approved the appointment of David Pernock to the position of Chief Operating Officer, effective as of September 1, 2018.
Tue, 11 Sep 2018
14:41:31 +0000
Does Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Fall With The Market?
If you own shares in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measureRead More...
Fri, 07 Sep 2018
12:32:12 +0000
Baxter's Actifuse Flow Bone Graft Substitute Gets FDA Nod
The latest FDA approval for Baxter's (BAX) Actifuse Flow bone graft is likely to boost its Advanced Surgery segment.
Wed, 05 Sep 2018
14:21:02 +0000
Agios (AGIO) Assigns Ex-Celgene Executive to CEO Position
Agios Pharmaceuticals (AGIO) names Dr. Jacqualyn Fouse as its next chief executive officer from Feb 1, 2019 onward.
Tue, 04 Sep 2018
20:30:00 +0000
Eagle Pharmaceuticals, Inc. to Present at Morgan Stanley 16th Annual Global Healthcare Conference
Eagle Pharmaceuticals, Inc. announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will pr
Thu, 30 Aug 2018
11:00:00 +0000
Eagle Pharmaceuticals Concludes Enrollment of Second Safety and Efficacy Study at Hajj to Evaluate RYANODEX for Exertional Heat Stroke
Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (EGRX) today announced completion of enrollment of the Company’s second clinical study to further evaluate the safety and efficacy of RYANODEX® (dantrolene sodium for injectable suspension) for the treatment of exertional heat stroke (“EHS”), an investigational new indication for the product.
Tue, 28 Aug 2018
11:30:00 +0000
Analysis: Positioning to Benefit within MannKind, Chimerix, Superior Energy Services, Marinus Pharmaceuticals, Airgain, and Eagle Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MannKind ...
Thu, 23 Aug 2018
11:00:00 +0000
Eagle Pharmaceuticals Named to Fortune 100 List of Fastest-Growing Companies
Eagle Pharmaceuticals, Inc. (EGRX) (“Eagle” or “the Company”) today announced that the Company has been named to the Fortune 100 List of Fastest-Growing Companies, ranking 16th overall, including achieving the #1 positions for EPS 3-year growth of 392% and revenue 3-year growth of 109%. “We are extremely proud of how our team has executed on our overall growth strategy. Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products.
Wed, 22 Aug 2018
13:02:00 +0000
Eagle Pharmaceuticals Announces New Patent Issued for BENDEKA
– BENDEKA protected by 16 patents running from 2026 through 2033 –
Mon, 20 Aug 2018
19:34:38 +0000
Edited Transcript of EGRX earnings conference call or presentation 7-Aug-18 12:30pm GMT
Q2 2018 Eagle Pharmaceuticals Inc Earnings Call
Tue, 07 Aug 2018
12:15:12 +0000
Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Top Estimates
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 15.85% and 14.53%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Tue, 07 Aug 2018
11:09:33 +0000
Eagle Pharmaceuticals: 2Q Earnings Snapshot
On a per-share basis, the Woodcliff Lake, New Jersey-based company said it had profit of 17 cents. Earnings, adjusted for non-recurring costs and stock option expense, were 95 cents per share. The specialty ...
Tue, 07 Aug 2018
10:50:00 +0000
Eagle Pharmaceuticals, Inc. Reports Second Quarter 2018 Results
-- Q2 2018 net income was $0.18 per basic and $0.17 per diluted share and adjusted non-GAAP net income of $0.99 per basic and $0.95 per diluted share --
Tue, 07 Aug 2018
10:30:00 +0000
Eagle Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM Eastern ...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "It [ValueForum] has provided me with eye opening information on a wide scale. The collective wisdom of the membership is astounding and somewhat intimidating; but useful input is appreciated pretty universally." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards